The hazard ratio is prone to selection bias. At baseline, the proportion of patients with hormone-receptor positive tumor is the same in the control and in the treatment group because randomization ensures covariate balancing in expectation (Fig. 1D). The gene discussed is NR4A1; the disease is neoplasm.